Media ReleasesImmutep

View All Immutep News


Immutep Reports Positive Phase II TACTI-002 Data


Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002 study. The data relates to the data cut-off date of 20 March 2020 and shows improving efficacy results.

The results are being presented today as a poster short talk audio presentation as part of the high-impact paper presentation program by TACTI-002 Principle Investigator, Dr Martin Forster of University College London Hospitals NHS Foundation at the American Association for Cancer Research (AACR) Virtual Annual Meeting. 

For more information, download the attached PDF.
Download this document